Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation

  • End date
    Sep 25, 2028
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 14 February 2022
renal function
pelvic mri
adenocarcinoma of rectum
rectal surgery
total mesorectal excision


Preoperative radiation and chemotherapy is the standard treatment for local advanced rectal cancer. The addition of oxaliplatin to capecitabine combined with radiotherapy does not improve local control and long-term survival. Most importantly,chemoradiotherapy significantly increased surgical complication and poor long-term quality of life .In the absence of effective measures of predicting chemo-sensitivity, there is considerable risk of using any two-drug regimen for neoadjuvant therapy. Simultaneous use of the three chemotherapeutic drugs may be able to reduce the likelihood of resistance to both dual drug regimen and single drug regimen. The purpose of this study is to compare the efficacy and safety of three chemotherapeutic regimen known as FOLFOXIRI (the drug 5-fluorouracil, oxaliplatin, Irinotecan) with standard radiotherapy combined with capecitabine in neoadjuvant therapy for local advanced rectal cancer. The drugs in the FOLFOXIRI regimen are all FDA(Food and Drug Administration) approved and have been used routinely to treat patients with advanced colorectal cancer.


Outline: This is a multicenter,prospectively,randomized control ,phase III clinical study.Patients are stratified according to the distance from the tumor to the anal margin5cm>5cm and randomized to 1 of 2 treatment regimen.Patients will receive full supportive care while on this study.


Primary: To compare neoadjuvant chemotherpay of FOLFOXIRI with conventional capecitabine single-agent radiotherapy in local advanced rectal cancer with respect to 3-year disease free survival rate (DFS) .

  1. To compare postoperative 3-year local recurrence rate, 3-year distance metastasis free survival rate, 3-year overall survival between neoadjuvant FOLFOXIRI with capecitabine single-agent radiotherapy groups.
  2. To compare R0 Resection rate and surgical complication between the two groups.
  3. To evaluate the tumor regression grade(TRG) between the two groups.
  4. To evaluate the adverse event profile and Long term quality of life between the two groups.

Condition Rectal Cancer
Treatment XELOX, FOLFOXIRI, Chemoradiotherapy, TME operation, efficacy evaluation
Clinical Study IdentifierNCT03671252
SponsorSun Yat-sen University
Last Modified on14 February 2022


Yes No Not Sure

Inclusion Criteria

Age: 18 to 75 years old
Histological diagnosis of rectal adenocarcinoma
Distance form anal margin 5cm: cT3-4aN + M0, there is no distant metastasis, lymph node positive, or the tumor breaking through the muscular layer, no invasion of the adjacent organs , positive MRF, it is estimated that R0 resection can be performed
From the anal margin>5cm: cT3c-4aN+M0, there is no distant metastasis, lymph node positive, or the tumor breaking through the muscular layer with invading the mesorectum more than 5mm, no invasion of the adjacent organs, positive MRF, it is estimated that R0 resection can be performed
Preoperative staging method: All patients undergoing anal examination, high-resolution MRI and/or EUS for preoperative staging. The diameter of parenteral lymph node 10mm, lymph node shape or the MRI characteristics is consistent with typical lymph node metastasis. If combined with EUS, the material should be submitted to the central assessment team for judgment when there is a contradiction in the staging method. Preoperative chest and abdomen CT, pelvic MRI are used for excluding distant metastasis
Confirmed as the lower edge of tumor is located within 12 cm from the anal margin by MRI examination
There is no signs of intestinal obstruction, or obstruction of intestinal after treating with proximal colostomy has been relieved
Patients did not previously receive rectal surgery, chemotherapy or radiation therapy , biological treatment , except for endocrine therapy
ECOG Performance Status :0-1
Life expectancy: more than 2 years
Laboratory valuesHematology: white blood cell count>4000/mm3; Platelet count>100000/mm3; Hemoglobin >10g/dL; Liver function: SGOT and SGPT < 1.5 upper limit of normal(ULN); Bilirubin< 1.5mg/dL; Renal function :Creatinine <1.8mg/dL

Exclusion Criteria

Tumor invasion of surrounding tissue organs (T4b) by preoperative staging assessment
Obturator lymph node metastasis
Arrhythmia requires treatment with antiarrhythmia (except for beta-blockers or digoxin), symptomatic coronary artery disease, myocardial ischemia (myocardial infarction within the last 6 months) or congestive heart failure exceeding NYHA class II
Severe hypertension with poor control
History of HIV infection or active phase of chronic hepatitis B or C infection with high copy viral DNA
Other active serious infections according to NCI-CTC version 4.0
There is preoperative evidence for distant metastasis outside pelvis
Cachexia and organ function decompensation
History of pelvic or abdominal radiotherapy
Multiple primary cancer
Patients with epilepcy requiring treatment ( steroids or antiepileptic treatment)
History of other malignant tumors within 5 years, except for cured cervical carcinoma in situ or skin basal cell carcinoma
Drug abuse and medical, psychological or social conditions interfering patient participation in research or the evaluation of research results
Any allergy to clinical research drugs or any drugs associated with this study
Any unstable condition or condition that may endanger safety and compliance of patients
Pregnancy or the lactating female without adequate contraception
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note